Profound Medical Clarifies Recent Insider Purchases

ryanniesMay 18, 2022

Toronto, May 18, 2022 (GLOBE NEWSWIRE) —Recent release by Profound Medical Corp. (NASDAQ: PROF; TSX: PRN), which is part of the insider, in response to investor inquiries regarding insider trading activities. Regarding market stock purchases (“Deep” or “Company”), we today provided the following explanation:

“We are not currently submitting a domestic form to the US Securities and Exchange Commission. Form 4: Statement of Beneficial Ownership ChangesThrough this, many US-based investors monitor insider trading, and as a result, some shareholders are likely to be a recent third party based on submissions to the Electronic Disclosure System (SEDI) by Canadian insiders. I asked a question about the report. “Profound CEO and Chairman Arun Menawat said. “After the power outage period in the first quarter of 2022 was lifted, Independent Chief Executive Officer Brian Eracott and I purchased additional company shares on Nasdaq for a total of approximately US $ 763,000. These transactions are summarized below. I am. “

Brian Eracot: Purchased 50,000 shares on May 12, 2022 at a price of US $ 7.05 per share. Eracot currently holds 68,000 profound shares.
Arummenawat: We purchased 30,516 shares on May 12, 2022 and 30,000 shares on May 13, 2022 at prices of $ 6.6548 and $ 6.9235, respectively. Dr. Menawat currently holds 408,796 profound shares.

This information is currently provided solely to assist our shareholders and Profound has no plans to issue any further press releases regarding insider trading.

About Profound Medical Co., Ltd.

Profound is a commercial medical device company that develops and sells customizable, incision-free therapies for excision of lesioned tissue.

Deep has commercialized TULSA-PRO^®, Real-time MRI, robot-driven transurethral ultrasound, and closed-loop temperature feedback control. TULSA-PRO^® Is designed to provide surgeon-defined, customizable, predictable, radiation-free ablation of prostate volume while actively protecting the urethra and rectum to maintain the patient’s natural functional capacity. increase. TULSA-PRO^® Possible flexible technology for customizable prostatectomy, including mid-term cancer, localized radiation recurrent cancer, retention and hematuria relief of locally advanced prostate cancer, and transitional zones of massive benign prostatic hyperplasia (“BPH”) There is sex. TULSA-PRO^® It has the CE mark, is approved by Health Canada, and 510 (k) is approved by the US Food and Drug Administration (“FDA”).

Profound has also commercialized Sonalleve^®An innovative treatment platform with the CE mark for the treatment of uterine fibroids and the treatment of palliative pain in bone metastases.Sonarive^® It is also approved by the National Bureau of Medical Products of China for the non-invasive treatment of uterine fibroids and FDA approved for the treatment of osteoid osteoma under a humanitarian device exemption.We are in the early stages of exploring additional potential therapeutic markets for Sonarive^® This technique has been shown to have clinical applications such as non-invasive resection of abdominal cancer and hyperthermia for cancer treatment.

Description of future prospects

This release includes, but is not limited to, expectations regarding the effectiveness of Profound’s technology in the treatment of prostate cancer, BPH, uterine myoma, palliative pain treatment, and osteoid osteoma. Contains a description. Often, but not always, forward-looking statements are “planned,” “expected,” “expected,” “planned,” “intended,” “intended,” and “expected.” Do, “believe”, “suggest” or variation (including negative variations) of such words or phrases, or “potential”, “possible”, or result of a particular action, event, or result. Occurs or is achieved, stating that there is, is possible, is possible, or is possible. Such a statement is based on the current expectations of profound management. Future events and situations described in this release may or may not occur by a specific date and may or may not occur at all, known and unknown risks affecting us, such as medical device industry, regulatory risks, etc. It can vary significantly as a result of factors and uncertainties. Approval, redemption, economic factors, general stock markets, and risks associated with growth and competition. Profound has sought to identify important factors that may cause actual actions, events, or outcomes to differ materially from those described in the forward-looking statements, but the actions, events, or outcomes are expected or estimated. , Or there may be other factors that cause something different than intended. Forward-looking statements are not guaranteed. In addition, there are uncertainties about the spread of the COVID-19 virus and its impact on Profound’s business, its product demand, global supply chain, and general economic activity. Unless required by applicable securities law, forward-looking statements are stated only as of the date they were created, and Profound may provide new information, future events, or by law. Unless required.

For more information, please contact:

Stephen Kilmer
Public relations activities for investors
skilmer@profoundmedical.com

T: 647.872.4849